Company

Company

Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Refuge Biotechnologies

Main focus: CAR-T cells for cancer treatment

Company stage: Clinical

Diseases: Breast cancer, head and neck cancer, liver cancer, diffuse large B-cell lymphoma (DLBCL)

Genome editing tool: CRISPR-Cas9/dCas9

Funding stage: Private

Location: Menlo Park, CA, USA

Website: https://refugebiotech.com/

Pipeline: https://refugebiotech.com/#programs

Partnerships: 3SBio

Refuge Biotech is a pre-clinical stage cancer immunotherapy company. The company uses a modified dCas9-based platform to engineer its CAR-T cell therapies, mainly for the treatment of solid tumours. Its dCas9 system is used in two ways: CRISPRa (activation) and CRISPRi (interference), which lead to either transcriptional activators or repression of target genes.

Refuge Biotechnologies Inc.

Your Latest CMN News

CMN Weekly (19 April 2024) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

A Secondary Checkpoint Refines CRISPR Precision

New findings highlight a secondary conformational checkpoint in CRISPR-Cas9 that significantly enhances its accuracy in gene editing.

Cancer's Weak Point Is Its Metabolism, CRISPR...

American researchers have developed a novel CRISPR-based platform to identify and characterise essential nutrient transporters that support cancer...

Next-Generation CRISPR Screening Libraries Without...

Sponsored content

Founded in 2018, Vivlion is a spin-out of Goethe University Frankfurt. Its mission is to provide innovative gene-editing reagents and screening...

CMN Weekly (12 April 2024) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

Scientists use CRISPR to develop new detection...

Scientists in China describe a sensitive and selective CRISPR-Cas12-based assay for the detection of a protein that is implicated in obesity and...

Company: Refuge Biotechnologies

Search CRISPR Medicine